The Federal Drug Administration (FDA) is close to relaxing some of its rules regarding the development of new HIV drugs. In order to avail long-term HIV patients of the constantly changing drugs they need to avoid mutation of the virus, the FDA is looking to curtail some of their more onerous research and regulatory requirements.

Read the story.